Novartis pelacarsen fails late-stage cholesterol study
Novartis AG says its experimental cholesterol drug pelacarsen failed in a late-stage study, removing an anticipated large prospective medicine-market opportunity.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.